Diabetic Retinopathy and Maculopathy

Intravitreal injections (anti-VEGF: Avastin®, Lucentis®, Eylea® or Steroid: Triamcinolone®, Ozurdex®) , LASER (NIDEK® laser) or Vitrectomy surgery.

The macula is the part of the eye that helps to provide us with our central vision. Diabetic maculopathy is when the macula sustains some form of damage. One such cause of macular damage is from diabetic macular oedema whereby blood vessels near to the macula leak fluid or protein onto the macula.

If the leakages cause the retina to harden and exudates (deposits of fat from the blood) become significantly large and close to the fovea, then the condition is termed as Clinically Significant Macular Oedema (CSMO).

Mild macular oedema may resolve itself without treatment but most people will need the first line of diabetic maculopathy treatment which is laser photocoagulation treatment.Other treatments include having injections of what are called anti-VEGF drugs (anti-vascular endothelial growth factor), such as Lucentis or Avastin. At the time of writing Avastin and Lucentis have not been approved for use in treating diabetic macular oedema by NICE but an appeal is underway by health charities to reverse the decision.